Meeting
2020 ASCO Virtual Scientific Program
Outcome in patients with refractory high-risk neuroblastoma.
Authors
Amir Bari Siddiqui
University of Chicago Medical Center, Chicago, IL
Amir Bari Siddiqui , Akosua Oppong , Cindy Yuan , Guimin Gao , Rochelle Bagatell , Katherine Berg , Elizabeth Sokol , Kyle MacQuarrie , Navin R. Pinto , Anurekha Gollapudi , Rajen Mody , Ian Wolfe , Suzanne Shusterman , Jennifer Foster , Valeria Smith , Susan Lerner Cohn , Ami Vijay Desai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10537)
DOI
10.1200/JCO.2020.38.15_suppl.10537
Abstract #
10537
Poster Bd #
424
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.
First Author: Godfrey Chi-Fung Chan
Poster
2022 ASCO Annual Meeting
Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.
First Author: Benjamin Lerman
Poster
2022 ASCO Annual Meeting
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.
First Author: Shakeel Modak
Poster
2023 ASCO Annual Meeting
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).
First Author: Emily Gustava Greengard